Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Kawasaki Medical School, Kurashiki, Japan.
J Thorac Oncol. 2010 May;5(5):585-90. doi: 10.1097/JTO.0b013e3181d60fd7.
Cyclooxygenase-2 (COX-2) is constitutively overexpressed in a variety of epithelial malignancies and is usually associated with a poor prognosis. COX-2-derived prostaglandin E2 transforms CD4+CD25+ T regulatory (Treg) cells (Tregs), and Tregs are thought to moderate the antitumor immune response. Herein, we investigated the prognostic value of tumor-infiltrating Treg cells and their correlation with COX-2 expression in resected non-small cell lung cancer (NSCLC).
Intratumoral COX-2 and Treg expression were retrospectively assessed using immunohistochemistry in paraffin-embedded samples from 100 patients who had undergone complete resections for NSCLC. The expressions of COX-2 and Foxp3, which was most specific Treg cell marker, were compared with the clinicopathological variables, and the correlation between Foxp3+ Tregs and COX-2 expression was analyzed.
The recurrence-free survival (RFS) of patients with elevated COX-2 expression was significantly worse than that of patients without COX-2 expression. Tumor-infiltrating Foxp3-positive lymphocytes were positively correlated with COX-2 expression. The median count for Foxp3-positive lymphocytes was 3 (minimum-maximum, 0-24) in 10 high-power fields. The RFS of patients with tumors containing >or=3 Foxp3-positive cells (Foxp3 expression group) was significantly worse than that of patients with tumors containing <3 Foxp3-positive cells. In a multivariate analysis, only nodal status was an independent predictor of a significantly shorter RFS. However, in node-negative NSCLC, Foxp3 expression was an independent predictor of a significantly shorter RFS.
Tumor-infiltrating Foxp3+ Tregs were positively correlated with intratumoral COX-2 expression and were associated with a worse RFS, especially among patients with node-negative NSCLC.
环氧化酶-2(COX-2)在多种上皮恶性肿瘤中持续过表达,通常与预后不良相关。COX-2 衍生的前列腺素 E2 可转化 CD4+CD25+调节性 T 细胞(Treg),而 Treg 被认为可调节抗肿瘤免疫反应。在此,我们研究了 COX-2 表达与肿瘤浸润性 Treg 细胞在非小细胞肺癌(NSCLC)患者中的相关性及其在 NSCLC 根治性切除术后的预后价值。
采用免疫组织化学方法检测 COX-2 和 Treg 在 100 例 NSCLC 根治性切除患者石蜡包埋标本中的表达。比较 COX-2 和 Foxp3(最特异的 Treg 细胞标志物)的表达与临床病理变量之间的关系,并分析 Foxp3+Treg 与 COX-2 表达的相关性。
COX-2 高表达患者的无复发生存(RFS)明显差于 COX-2 低表达患者。肿瘤浸润 Foxp3 阳性淋巴细胞与 COX-2 表达呈正相关。10 个高倍视野中 Foxp3 阳性淋巴细胞的中位数为 3(最小值-最大值,0-24)。Foxp3 阳性细胞数≥3(Foxp3 表达组)的患者 RFS 明显差于 Foxp3 阳性细胞数<3 的患者。多因素分析显示,只有淋巴结状态是 RFS 显著缩短的独立预测因素。然而,在淋巴结阴性 NSCLC 患者中,Foxp3 表达是 RFS 显著缩短的独立预测因素。
肿瘤浸润 Foxp3+Treg 与肿瘤内 COX-2 表达呈正相关,与 RFS 较差相关,尤其是淋巴结阴性 NSCLC 患者。